South Delhi Pharma, New Delhi, India
LIBTAYO (cemiplimab-rwlc) injection. FDA-Approved. To treat CSCC
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
LIBTAYO (cemiplimab-rwlc) injection is a prescription medicine. LIBTAYO (cemiplimab-rwlc) injection is used to treat metastatic cutaneous squamous cell carcinoma (CSCC).
INDICATIONS AND USAGE
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
DOSAGE FORMS & STRENGTHS: Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial.
Manufactured By: Regeneron
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “LIBTAYO (cemiplimab-rwlc) FDA Approved” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.
In September 2018, it was approved by the U.S. Food and Drug Administration (FDA) for treating people with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. It was approved for medical use in the European Union in June 2019. It was approved for medical use in Australia in July 2020.
Cemiplimab is the first FDA approval of a medication specifically for advanced cutaneous squamous cell carcinoma (CSCC).